{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T23:22:37Z","timestamp":1787440957850,"version":"build-2736575974"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002850","name":"CONICYT FONDECYT","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002850","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.biopha.2026.119636","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:17:09Z","timestamp":1781018229000},"page":"119636","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Purine derivatives as potential agents against Chagas disease: Ex vivo, in vitro, in silico evaluation, and identification of targets in Trypanosoma cruzi"],"prefix":"10.1016","volume":"200","author":[{"given":"Thal\u00eda","family":"Delgado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alonzo","family":"Gonz\u00e1lez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes Didier","family":"Garnham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emir","family":"Salas-Sarduy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gildardo","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rogelio","family":"G\u00f3mez-Escobedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjam\u00edn","family":"Nogueda-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7620-2459","authenticated-orcid":false,"given":"Cristian O.","family":"Salas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119636_bib1","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1056\/NEJMra1410150","article-title":"Chagas' disease","volume":"373","author":"Bern","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119636_bib2","first-page":"343","article-title":"[What is not searched, it is difficult to find: Chagas' disease","volume":"17","author":"Briceno","year":"2016","journal-title":"G Ital. Cardiol."},{"key":"10.1016\/j.biopha.2026.119636_bib3","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/em.21839","article-title":"Unveiling benznidazole's mechanism of action through overexpression of DNA repair proteins in Trypanosoma cruzi","volume":"55","author":"Rajao","year":"2014","journal-title":"Environ. Mol. Mutagen."},{"key":"10.1016\/j.biopha.2026.119636_bib4","doi-asserted-by":"crossref","first-page":"8459","DOI":"10.1021\/acs.jafc.9b02681","article-title":"Synthesis, antiviral activity, and mechanisms of purine nucleoside derivatives containing a sulfonamide moiety","volume":"67","author":"He","year":"2019","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.biopha.2026.119636_bib5","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrd4010","article-title":"Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases","volume":"12","author":"Jordheim","year":"2013","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.biopha.2026.119636_bib6","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(02)00788-X","article-title":"Nucleoside analogues and nucleobases in cancer treatment","volume":"3","author":"Galmarini","year":"2002","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2026.119636_bib7","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/cbdd.14145","article-title":"Design, synthesis, and anticancer evaluation of N(6) -hydrazone purine derivatives with potential antiplatelet aggregation activity","volume":"101","author":"Wei","year":"2023","journal-title":"Chem. Biol. Drug. Des."},{"key":"10.1016\/j.biopha.2026.119636_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105096","article-title":"Potential antibacterial ethanol-bridged purine azole hybrids as dual-targeting inhibitors of MRSA","volume":"114","author":"Hu","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.biopha.2026.119636_bib9","first-page":"1914","article-title":"Antibacterial and antivirulence effect of 6-N-hydroxylaminopurine in Listeria monocytogenes","volume":"45","author":"Krajewski","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biopha.2026.119636_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127512","article-title":"Design and synthesis of purine connected piperazine derivatives as novel inhibitors of Mycobacterium tuberculosis","volume":"30","author":"Konduri","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.biopha.2026.119636_bib11","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1021\/acsinfecdis.0c00105","article-title":"Structure-activity relationship exploration \u00ba\u00baof 3\u2032-deoxy-7-deazapurine nucleoside analogues as anti-Trypanosoma brucei agents","volume":"6","author":"Hulpia","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.biopha.2026.119636_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.127957","article-title":"Synthesis and anti-trypanosomal activity of 3\u2032-fluororibonucleosides derived from 7-deazapurine nucleosides","volume":"40","author":"Nguyen","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.biopha.2026.119636_bib13","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1515\/ap-2017-0070","article-title":"In vitro effects of purine and pyrimidine analogues on Leishmania donovani and Leishmania infantum promastigotes and intracellular amastigotes","volume":"62","author":"Azzouz","year":"2017","journal-title":"Acta Parasitol."},{"key":"10.1016\/j.biopha.2026.119636_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113290","article-title":"Synthesis and evaluation of 3\u2032-fluorinated 7-deazapurine nucleosides as antikinetoplastid agents","volume":"216","author":"Bouton","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.biopha.2026.119636_bib15","doi-asserted-by":"crossref","first-page":"9287","DOI":"10.1021\/acs.jmedchem.8b00999","article-title":"Discovery of novel 7-aryl 7-deazapurine 3\u2032-deoxy-ribofuranosyl nucleosides with potent activity against Trypanosoma cruzi","volume":"61","author":"Hulpia","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2026.119636_bib16","doi-asserted-by":"crossref","first-page":"8847","DOI":"10.1021\/acs.jmedchem.9b01275","article-title":"Discovery of pyrrolo[2,3-b]pyridine (1,7-dideazapurine) nucleoside analogues as anti-Trypanosoma cruzi agents","volume":"62","author":"Lin","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2026.119636_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114165","article-title":"N(6)-modification of 7-deazapurine nucleoside analogues as Anti-Trypanosoma cruzi and anti-Leishmania agents: structure-activity relationship exploration and In vivo evaluation","volume":"231","author":"Lin","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.biopha.2026.119636_bib18","article-title":"Identification of compounds with activity against Trypanosoma cruzi within a collection of synthetic nucleoside analogs","volume":"12","author":"Barnadas-Carceller","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.biopha.2026.119636_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/ph14070638","article-title":"Novel purine chemotypes with activity against Plasmodium falciparum and Trypanosoma cruzi","volume":"14","author":"Martinez-Peinado","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.biopha.2026.119636_bib20","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.2174\/0929867322666150521091652","article-title":"Cruzipain: an update on its potential as chemotherapy target against the human pathogen Trypanosoma cruzi","volume":"22","author":"Branquinha","year":"2015","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.biopha.2026.119636_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0038385","article-title":"Repertoire, genealogy and genomic organization of cruzipain and homologous genes in Trypanosoma cruzi, T. cruzi-like and other trypanosome species","volume":"7","author":"Lima","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2026.119636_bib22","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1021\/jm901069a","article-title":"Identification and optimization of inhibitors of Trypanosomal cysteine proteases: cruzain, rhodesain, and TbCatB","volume":"53","author":"Mott","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2026.119636_bib23","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00243-24","article-title":"Identification of novel bromodomain inhibitors of Trypanosoma cruzi bromodomain factor 2 (TcBDF2) using a fluorescence polarization-based high-throughput assay","volume":"68","author":"Tavernelli","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2026.119636_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2024.1465672","article-title":"1,3,4-oxadiazoles as inhibitors of the atypical member of the BET family bromodomain factor 3 from Trypanosoma cruzi (TcBDF3)","volume":"15","author":"Alonso","year":"2024","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.biopha.2026.119636_bib25","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ijpara.2008.11.013","article-title":"Trypanosoma cruzi bromodomain factor 2 (BDF2) binds to acetylated histones and is accumulated after UV irradiation","volume":"39","author":"Villanova","year":"2009","journal-title":"Int. J. Parasitol."},{"key":"10.1016\/j.biopha.2026.119636_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14061294","article-title":"Design, synthesis, in silico studies and inhibitory activity towards Bcr-Abl, BTK and FLT3-ITD of new 2,6,9-trisubstituted purine derivatives as potential agents for the treatment of leukaemia","volume":"14","author":"Bertrand","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2026.119636_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103361","article-title":"New 2,6,9-trisubstituted purine derivatives as Bcr-Abl and Btk inhibitors and as promising agents against leukemia","volume":"94","author":"Bertrand","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.biopha.2026.119636_bib28","article-title":"Drug repurposing for trypanosomiasis: using machine learning models and polypharmacology to identify multitarget candidates","volume":"36","author":"Domingues","year":"2025","journal-title":"J. Braz. Chem. Soc."},{"key":"10.1016\/j.biopha.2026.119636_bib29","doi-asserted-by":"crossref","first-page":"27380","DOI":"10.1021\/acsomega.5c02998","article-title":"Antiproliferative and trypanocidal activity of ivermectin bioconjugates","volume":"10","author":"Sulik","year":"2025","journal-title":"ACS Omega"},{"key":"10.1016\/j.biopha.2026.119636_bib30","doi-asserted-by":"crossref","first-page":"5626","DOI":"10.3390\/molecules27175626","article-title":"Synthesis, leishmanicidal, trypanocidal, antiproliferative assay and apoptotic induction of (2-phenoxypyridin-3-yl)naphthalene-1(2h)-one derivatives","volume":"27","author":"Blanco","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2026.119636_bib31","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1002\/cmdc.201800206","article-title":"Synthesis and evaluation of the anticancer and trypanocidal activities of boronic tyrphostins","volume":"13","author":"Hiller","year":"2018","journal-title":"ChemMedChem"},{"key":"10.1016\/j.biopha.2026.119636_bib32","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/jphp.13273","article-title":"Drug repositioning: a brief overview","volume":"72","author":"Jourdan","year":"2020","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119636_bib33","first-page":"389","article-title":"Therapeutic activity and criterion of cure on mice experimentally infected with Trypanosoma cruzi","volume":"4","author":"Brener","year":"1962","journal-title":"Rev. Inst. Med. Trop. Sao Paulo"},{"key":"10.1016\/j.biopha.2026.119636_bib34","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1128\/AAC.40.11.2592","article-title":"Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase","volume":"40","author":"Buckner","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2026.119636_bib35","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0022-1759(94)90396-4","article-title":"A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay","volume":"170","author":"Ahmed","year":"1994","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.biopha.2026.119636_bib36","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0166-6851(03)00175-0","article-title":"Characterization of a lysosomal serine carboxypeptidase from Trypanosoma cruzi","volume":"131","author":"Parussini","year":"2003","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.biopha.2026.119636_bib37","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-12170-4","article-title":"Novel scaffolds for inhibition of Cruzipain identified from high-throughput screening of anti-kinetoplastid chemical boxes","volume":"7","author":"Salas-Sarduy","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119636_bib38","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1111\/febs.13719","article-title":"Overexpression of bromodomain factor 3 in Trypanosoma cruzi (TcBDF3) affects differentiation of the parasite and protects it against bromodomain inhibitors","volume":"283","author":"Alonso","year":"2016","journal-title":"FEBS J."},{"key":"10.1016\/j.biopha.2026.119636_bib39","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1758-2946-3-33","article-title":"Open Babel: an open chemical toolbox","volume":"3","author":"O'Boyle","year":"2011","journal-title":"J. Cheminf."},{"key":"10.1016\/j.biopha.2026.119636_bib40","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF chimera\u2013a visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.biopha.2026.119636_bib41","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13321-021-00522-2","article-title":"GNINA 1.0: molecular docking with deep learning","volume":"13","author":"McNutt","year":"2021","journal-title":"J. Cheminf."},{"key":"10.1016\/j.biopha.2026.119636_bib42","doi-asserted-by":"crossref","first-page":"W530","DOI":"10.1093\/nar\/gkab294","article-title":"PLIP 2021: expanding the scope of the protein-ligand interaction profiler to DNA and RNA","volume":"49","author":"Adasme","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biopha.2026.119636_bib43","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","article-title":"GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers","volume":"1-2","author":"Abraham","year":"2015","journal-title":"SoftwareX"},{"key":"10.1016\/j.biopha.2026.119636_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20235834","article-title":"Virtual screening using pharmacophore models retrieved from molecular dynamic simulations","volume":"20","author":"Polishchuk","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119636_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens10020212","article-title":"Assessing Trypanosoma cruzi parasite diversity through comparative genomics: implications for disease epidemiology and diagnostics","volume":"10","author":"Majeau","year":"2021","journal-title":"Pathogens"},{"key":"10.1016\/j.biopha.2026.119636_bib46","doi-asserted-by":"crossref","unstructured":"Alonso, V.L., Manarin, R., Perdomo, V., Gulin, E., Serra, E., Cribb, P., In Vitro Drug Screening Against all Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing \u03b2-galactosidase, 1940-087X, vol. 177, 2021, p. e63210.","DOI":"10.3791\/63210-v"},{"key":"10.1016\/j.biopha.2026.119636_bib47","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3390\/microorganisms11020476","article-title":"Impact of laboratory-adapted intracellular Trypanosoma cruzi strains on the activity profiles of compounds with anti-T. cruzi activity","volume":"11","author":"Sykes","year":"2023","journal-title":"Microorganisms"},{"key":"10.1016\/j.biopha.2026.119636_bib48","first-page":"1","article-title":"State-of-the-art in the drug discovery pathway for Chagas disease: a framework for drug development and target validation","volume":"14","author":"Gabaldon-Figueira","year":"2023","journal-title":"Res. Rep. Trop. Med."},{"key":"10.1016\/j.biopha.2026.119636_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007088","article-title":"Utilization of proliferable extracellular amastigotes for transient gene expression, drug sensitivity assay, and CRISPR\/Cas9-mediated gene knockout in Trypanosoma cruzi","volume":"13","author":"Takagi","year":"2019","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.biopha.2026.119636_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2022.134308","article-title":"An insight into the rational design of recent purine-based scaffolds in targeting various cancer pathways","volume":"1274","author":"Chaurasiya","year":"2023","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.biopha.2026.119636_bib51","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01834-17","article-title":"Identification of anti-Trypanosoma cruzi lead compounds with putative immunomodulatory activity","volume":"62","author":"Otta","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2026.119636_bib52","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1021\/acsinfecdis.5c00900","article-title":"Identification of antifungal agents AR-12 and fosmanogepix as anti-Trypanosoma cruzi drugs through an enhanced fluorogenic beta-galactosidase phenotypic screening assay","volume":"12","author":"Didier Garnham","year":"2026","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.biopha.2026.119636_bib53","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.3389\/fmicb.2024.1465672","article-title":"1,3,4-oxadiazoles as inhibitors of the atypical member of the BET family bromodomain factor 3 from Trypanosoma cruzi (TcBDF3)","volume":"15","author":"Alonso","year":"2024","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.biopha.2026.119636_bib54","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1021\/acsinfecdis.2c00057","article-title":"Essential bromodomain TcBDF2 as a drug target against Chagas disease","volume":"8","author":"Pezza","year":"2022","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.biopha.2026.119636_bib55","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.bbapap.2005.08.018","article-title":"Protein kinases as drug targets in trypanosomes and Leishmania","volume":"1754","author":"Naula","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.biopha.2026.119636_bib56","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.pt.2022.08.009","article-title":"Distinguishing functions of trypanosomatid protein kinases","volume":"38","author":"Cayla","year":"2022","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.biopha.2026.119636_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.104857","article-title":"Identification of inhibitors for the transmembrane Trypanosoma cruzi eIF2alpha kinase relevant for parasite proliferation","volume":"299","author":"Marcelino","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2026.119636_bib58","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-97490-2","article-title":"The gene repertoire of the main cysteine protease of Trypanosoma cruzi, cruzipain, reveals four sub-types with distinct active sites","volume":"11","author":"Santos","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119636_bib59","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1021\/tx200211v","article-title":"Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety","volume":"24","author":"Meanwell","year":"2011","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.biopha.2026.119636_bib60","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.biopha.2026.119636_bib61","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2026.119636_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112290","article-title":"hERG toxicity assessment: useful guidelines for drug design","volume":"195","author":"Garrido","year":"2020","journal-title":"Eur. J. Med. Chem."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226006724?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226006724?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T22:58:43Z","timestamp":1787439523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226006724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":62,"alternative-id":["S0753332226006724"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119636","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Purine derivatives as potential agents against Chagas disease: Ex vivo, in vitro, in silico evaluation, and identification of targets in Trypanosoma cruzi","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119636","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119636"}}